The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

Abstract

BackgroundPolycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.MethodsCarotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month – baseline) ± standard deviation.ResultsNineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls −0.17 ± 0.26 but not PCOS −0.12 ± 0.28; between groups difference, 95% confidence interval = −0.14 – 0.26, P = 0.41. No significant changes were noted in cIMT or RHI.ConclusionsSix months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3–4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.Trial registrationClinical trial reg. no. ISRCTN48560305. Date of registration 22/05/2012.

Weight Management Interventions in Women with and without PCOS: A Systematic Review

“…The search returned 3264 articles ( Figure 1 ). Fifty-nine full text articles were retrieved for further evaluation and 17 articles [ 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ] reporting 14 studies met the inclusion criteria. Of these 17 articles, one study was reported across two articles [ 31 , 32 ] and one study [ 35 ] reported data across different time points [ 36 , 37 ].…”

“…Interventions varied across the included studies (diet, diet + behavior change program, diet + Metformin, diet + anti-obesity drug, anti-obesity drug, diet + anti-obesity drug + exercise, bariatric surgery, and various exercise training programs), as did the duration of interventions. Nine studies were designed with the specific aim of weight loss [ 34 , 37 , 38 , 39 , 41 , 42 , 43 , 45 , 46 ], while the remaining five studies did not state if the aim was weight loss [ 30 , 31 , 33 , 40 , 44 ]. The sample size of the studies varied from 31 to 1016.…”

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial

“…Glucagon-like peptide 1 receptor agonists (GLP-1RA) cause weight loss in patients with T2D and obesity, and have been tested in PCOS in smaller studies. [3][4][5][6][7] None of these studies was placebo-controlled, and often metformin was allowed as a pre-or co-medication. Therefore, we performed a randomized clinical trial (RCT) investigating whether monotherapy with the GLP-1RA liraglutide could reduce liver fat content, VAT and the prevalence of NAFLD in women with PCOS.…”

Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome

“…In another study, 6-month intervention with liraglutide was associated with significant reduction in atherothrombosis markers, including inflammation, endothelial function and clotting. The positive effect equally affected young obese women with PCOS and controls [58].…”

“…Lindenberg [55] x / Kahal et al [58] x / / Jensterle Sever et al [53] x / x / / Jensterle et al [60] x x x / x Jensterle et al [56] x x Jensterle et al [57] x x x x…”